Results 261 to 270 of about 517,911 (354)

Extent and Incidence of Pseudo‐Worsening of Kidney Function Due to Oral Antitumor Therapeutics in the AMBORA Cohort: An Analysis of Real‐World Data

Clinical Pharmacology &Therapeutics, EarlyView.
A considerable number of oral antitumor therapeutics (OAT) has the potential for causing pseudo‐worsening of kidney function (PW) due to inhibition of renal creatinine secretion, i.e., kidney function is unaffected, while creatinine‐based calculation of glomerular filtration rate (eGFR) erroneously indicates an impaired kidney function.
Michael I. Sponfeldner, Pauline Dürr, Phyllis Lensker, Katja Gessner, Lisa Cuba, Rainer Fietkau, Markus F. Neurath, Bernd Wullich, Marianne Pavel, Carola Berking, Matthias W. Beckmann, Andreas Mackensen, Frank Dörje, Martin F. Fromm   +13 more
wiley   +1 more source

Low-normal thyroid function and cardio-metabolic risk markers

, 2018
Lynnda Wind
openalex   +1 more source

Association between asthma and thyroid function as well as thyroid hormone sensitivity indicators: an NHANES study. [PDF]

Eur J Med Res
Li K, Ding Q, Liu R, Lin S, Qiu R, Wu G.
europepmc   +1 more source

Clinical Safety of Extended Interval Dosing of Nivolumab in Patients with Melanoma

Clinical Pharmacology &Therapeutics, EarlyView.
Extended interval dosing regimens of immune checkpoint inhibitors have been implemented widely. However, their approval was mainly based on pharmacokinetic modeling and simulations. Consequently, comparative safety data of extended interval dosing regimens in a real‐world setting are limited.
Ruben Malmberg, Maaike M. Hofman, Fatima Ashad, Alaa Daloul, Stefani Oosterveld, Edwin A. Basak, Esther Oomen‐de Hoop, Astrid A. M. van der Veldt, Arjen Joosse, Roelof W. F. van Leeuwen, Ron H. J. Mathijssen   +10 more
wiley   +1 more source

Thyroid Functions in Nonthyroidal Illness

, 1984
Hitoshi Suzuki, Masaki Hiraiwa, Yoshinobu Suzuki, Y Hashigami, Shin-Ichi Shimoda   +4 more
openalex   +2 more sources

Reevaluating the standard: A bidirectional Mendelian randomization study of autoimmune thyroiditis and thyroid function. [PDF]

Medicine (Baltimore)
Sun X, Pei S, Liao H, Yu C, Yang Y, Pan M.   +5 more
europepmc   +1 more source

Two Pillars of My Path in Cytopathology: Mentorship From Training to Practice

Diagnostic Cytopathology, EarlyView.
ABSTRACT Mentorship has been a cornerstone of my professional development in cytopathology, shaping both my diagnostic acumen and academic identity. Under the guidance of Dr. Claire Michael during residency and fellowship, I was introduced to a culture of intellectual rigor, systems thinking, and continuous improvement.
Hamza N. Gokozan
wiley   +1 more source

Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case Series

Diagnostic Cytopathology, EarlyView.
ABSTRACT Telomerase reverse transcriptase promoter (TERTp) mutations are associated with aggressive thyroid cancer and are most frequently found in anaplastic and poorly differentiated thyroid cancer. Pre‐operative thyroid nodule molecular testing can detect TERTp, denoting a high risk of malignancy and possible aggressive clinical features such as ...
Amir Harari, Jennifer Huiras, Yang Chen, Mohammed Alshalalfa, Yangyang Hao, Joshua P. Klopper, Richard T. Kloos, Bianca J. Vazquez   +7 more
wiley   +1 more source

Exploring the associations of the triglyceride‒glucose index with thyroid function in subclinical hypothyroid patients: a cross-sectional study. [PDF]

Lipids Health Dis
Inayat F, Shams S, Ullah N, Ahmad Shah AW, Haq IU.   +4 more
europepmc   +1 more source

Cytopathologic Features of Metastatic Malignant Mesothelioma With SMARCB1 (INI‐1) Deficient Diagnosed by Ultrasound‐Guided Fine‐Needle Aspiration: A Case Report

Diagnostic Cytopathology, EarlyView.
ABSTRACT Malignant mesothelioma (MM) is a rare yet aggressive neoplasm that arises from mesothelial cells lining the thoracic and abdominal cavities, the pericardium, and the tunica testis. Characterized by rapid progression, high invasiveness, and a poor prognosis, MM poses significant clinical challenges. SMARCB1, also referred to as INI‐1, hSNF5, or
Jun Yang, Juandi Liu, Jing Jin, Deng Pan, Lei Shao   +4 more
wiley   +1 more source